Do not miss out presentation on Thuesday 20, June at 9:40 AM

Session: ACTIVATION OF ENDOGENOUS AND EXPANSION OF UNMODIFIED GAMMA DELTA T CELLS

EVICTION-2 Clinical Trial: Combining ImmunoCytokines and ICT1 to Expand Endogenous Gamma9Delta2 T Cells

Aude De Gassart, PhD, Director, Preclinical Research, Imcheck Therapeutics

ICT01, an anti-BTN3A mAb, selectively activates ?9d2 T cells resulting in remodeling of the tumor microenvironment. However, the pharmacodynamic effects of ICT01 are dependent on the number of circulating gamma9d2 T cells, which is low in most advanced cancer patients. Preclinical studies showed that ICT01 plus IL-2 induces selective expansion of gamma9d2 T cells with minimal Treg expansion supporting an ongoing Phase I/IIa (EVICTION-2) in patients with advanced-stage solid tumors.

See the event website